• Cefpodoxime proxetil packaged and labeled.

click on thumbnail to zoom
SKU: C015

  Click 'Bulk Order' for 10 or more
Price: make selection(s)

Cefpodoxime Proxetil is a s a pro-drug tht is de-esterified in vivo to its active metabolite Cefpodoxime, a broad-spectrum, third-generation cephalosporin β-lactam antibiotic.  It is soluble in DMSO.

We also offer:

    CAS Number


    Molecular Formula


    Molecular Weight


    Mechanism of Action

    Like β-lactams, cephalosporins interfere with PBP (penicillin binding protein) activity involved in the final phase of peptidoglycan synthesis. PBP’s are enzymes which catalyze a pentaglycine crosslink between alanine and lysine residues providing additional strength to the cell wall. Without a pentaglycine crosslink, the integrity of the cell wall is severely compromised and ultimately leads to cell lysis and death. Resistance to cephalosporins is commonly due to cells containing plasmid encoded β-lactamases. However, like many cephalosporins, cefpodoxime is stable in the presence of β-lactamases.

    Storage Conditions

    -20°C, protect from light

    Tariff Code



    Cefpodoxime Proxetil is a broad-spectrum antibiotic which targets a wide variety of Gram-positive and Gram-negative bacteria especially those which cause otitis media and pharyngitis.<


    Microbiology Applications

    Cefpodoxime Proxetil is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive and Gram-negative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options.

    • Klebsiella pneumoniae 8 µg/mL - 64 µg/mL
    • Haemophilus influenzae 0.032 µg/mL – 1 µg/mL

    For a complete list of Cefpodoxime MIC values, click here.

    Cefpodoxime from TOKU-E was used as a reference compound when characterizing the extended-spectrum AmpC (ESAC) B-lactamase enzymes (Lahiri et al, 2014).

    In vitro kinetic modeling can be used to study the pharmacokinetic-pharmacodynamic modelling of the antibacterial activity of cefpodoxime.  This approach has more detailed information than the MIC about the time course of efficacy  (Liu et al, 2005).





    White or off-white powder



    Impurity Profile

    Impurity A| (6R,7R)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (cefpodoxime)|80210-62-4|C15H17N5O6S2|427.46| Impurity B| (1RS)-1-[[(1-methylethoxy)carbonyl]oxy]ethyl (6R,7R)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate (ADCA-analogue of cefpodoxime proxetil)||C20H25N5O8S2|527.57| Impurity C| (1RS)-1-[[(1-methylethoxy)carbonyl]oxy]ethyl (6R,7R)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylate (delta-2-cefpodoxime proxetil)||C21H27N5O9S2|557.59| Impurity D| (1RS)-1-[[(1-methylethoxy)carbonyl]oxy]ethyl (6R,7R)-7-[[(2E)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate (anti-cefpodoxime proxetil)||C21H27N5O9S2|557.59| Impurity E| (1RS)-1-[[(1-methylethoxy)carbonyl]oxy]ethyl (6R,7R)-3-(acetoxymethyl)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate (ACA-analogue of cefpodoxime proxetil)||C22H27N5O10S2|585.61| Impurity F| (1RS)-1-[[(1-methylethoxy)carbonyl]oxy]ethyl (6R,7R)-7-[[(2Z)-2-[(2-formylamino)thiazol-4-yl)-2-(methoxyimino)acetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate (N-formyl cefpodoxime proxetil)||C22H27N5O10S2|585.61| Impurity G||||| Impurity H| mixture of the diastereoisomers of 1-[[(1-methylethoxy)carbonyl]oxy]ethyl (6R,7R)-7-[[(2Z)-2-[2-[[(2R)-2-[[(2Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetyl]amino]-2-[(2R)-5-(methoxymethyl)-4-[[1-[[(1-methylethoxy)carbonyl]oxy]ethoxy]carbonyl]-3,6-dihydro-2H-1,3-thiazin-2-yl]acetyl]amino]thiazol-4-yl]-2-(methoxyimino)acetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate (cefpodoxime proxetil dimer||C43H52N10O19S4|1141.19|

    Water Content (Karl Fischer)


    Optical Rotation

    +35° to +48°


    (On Dried Basis): ≥96.0%

    Residue On Ignition


    Heavy Metals




    Borin MT (1991)  A review of the pharmacokinetics of defpodoxime proxetil. Drugs. 42(3):13-21

    Georgopapadakou NH (1992)  Mechanisms of action of Cephalosporin 3'-quinolone esters, carbamates, and tertiary amines in Escherichia coliAntimicrob. Agents and Chemother.  37(3):559-565

    Lahiri SD, Giacobbe RA, Johnstone MR and Alm RA (2014)  Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C β-lactamase enzyme. J. Antimicrob. Chemother. 69(11):2942–2946  

    Liu P, Rand KH, Obermann B and Derendorf H (2005)  Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Int. J. Antimicrob. Agents 25(2):120-129  PMID 15664481

    Wise R,  Andrews JM, Ashby JP and Thornber D (1990)  The in-vitro activity of cefpodoxime: a comparison with other oral cephalosporins.  J. Antimicrob. Chemother.  25(4):541–550  PMID 2351624

Other Items In This Category